These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 12576825

  • 1. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA.
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [Abstract] [Full Text] [Related]

  • 2. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 3. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS, Martinez AA, Horwitz EM, Gustafson GS, Gonzalez JA, Spencer WF, Brabbins DS, Dmuchowski CF, Hollander JB, Vicini FA.
    Cancer J Sci Am; 1997 Jun; 3(6):346-52. PubMed ID: 9403047
    [Abstract] [Full Text] [Related]

  • 4. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 6. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

  • 7. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ, Marion C, Fuks Z, Leibel SA.
    J Urol; 2003 Nov 01; 170(5):1828-32. PubMed ID: 14532785
    [Abstract] [Full Text] [Related]

  • 8. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, Kimming B.
    Strahlenther Onkol; 2006 Mar 01; 182(3):135-41. PubMed ID: 16520907
    [Abstract] [Full Text] [Related]

  • 9. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R, Wallner K, Merrick G, Virgin J, Orio P, True LD.
    J Urol; 2007 Nov 01; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [Abstract] [Full Text] [Related]

  • 10. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y, Hiratsuka J, Fujii T, Takenaka A, Fujisawa M.
    Urology; 2004 Sep 01; 64(3):556-60. PubMed ID: 15351592
    [Abstract] [Full Text] [Related]

  • 11. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1474-82. PubMed ID: 15964706
    [Abstract] [Full Text] [Related]

  • 12. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 13. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.
    J Urol; 2004 Mar 01; 171(3):1098-104. PubMed ID: 14767279
    [Abstract] [Full Text] [Related]

  • 14. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
    Phan TP, Syed AM, Puthawala A, Sharma A, Khan F.
    J Urol; 2007 Jan 01; 177(1):123-7; discussion 127. PubMed ID: 17162020
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

  • 16. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    Urology; 2004 Oct 15; 64(4):754-9. PubMed ID: 15491715
    [Abstract] [Full Text] [Related]

  • 17. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.
    J Urol; 2005 Sep 01; 174(3):882-7. PubMed ID: 16093980
    [Abstract] [Full Text] [Related]

  • 19. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Cancer J; 2001 Sep 01; 7(5):404-12. PubMed ID: 11693899
    [Abstract] [Full Text] [Related]

  • 20. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, Krauss DJ, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):416-23. PubMed ID: 16879929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.